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Abstract
Purpose of review Pre-participation cardiovascular evaluation with electrocardiography is
normal practice for most sporting bodies. Awareness about sudden cardiac death in
athletes and recognizing how screening can help identify vulnerable athletes have
empowered different sporting disciplines to invest in the wellbeing of their athletes.
Recent findings Discerning physiological electrical alterations due to athletic training from
those representing cardiac pathology may be challenging. The mode of investigation of
affected athletes is dependent on the electrical anomaly and the disease(s) in question.
Summary This review will highlight specific pathological ECG patterns that warrant assess-
ment and surveillance, together with an in-depth review of the recommended algorithm
for evaluation.
Introduction
Suddenty cardiac death (SCD) in athletes is the leading
cause of mortality during intense physical activity [1•].
The precise incidence of such tragedies has been difficult
to ascertain due to differences in methodologies and the
heterogenous nature of the populations studied. Current
studies report an incidence ranging from 0.5 to 13
deaths per 100,000 athletes [2–4], with a greater number
of deaths occurring in older (≥ 35 years) athletes. Most
deaths affect males and usually occur during or imme-
diately after exercise, suggesting that exercise is a trigger
for fatal arrhythmias in vulnerable athletes. Themajority
of cardiac disorders implicated in SCD can be broadly
categorised into structural or electrical diseases, which
may be genetic, congenital or acquired. Among young
athletes (G 35 years old), death is usually due to genetic
or congenital diseases such as the cardiomyopathies,
coronary artery anomalies, ion-channel disease or elec-
trical accessory pathways. Coronary artery disease is the
predominant cause of death in older athletes. Up to
80% of SCDs occur without any pre-warning signs [5,
6]; therefore, some form of screening process is neces-
sary to identify high-risk athletes on the assumption that
early identification of clinically silent cardiovascular dis-
ease empowers physicians to implement strategies to
prevent SCD. Given the diverse spectrum of diseases
implicated in exercise-related SCD, an elaborate investi-
gation protocol would be necessary to identify most
athletes. Such an approach would be cost prohibitive
because SCD in sports is rare.
The most pragmatic and cheapest method is to
screen with a health questionnaire and physical exami-
nation as recommended by the American Heart Associ-
ation, but this approach is associated with poor sensi-
tivity because most athletes are asymptomatic prior to
death. The 12-lead electrocardiogram (ECG) is the sim-
plest diagnostic tool in cardiology and is effective at
detecting a number of disorders linked to SCD, includ-
ing ion-channel disorders, electrical accessory pathways
and cardiomyopathies [7]. The Italian experience first
shed light on the importance of the ECG during screen-
ing of athletes more than a decade ago, with abnormal
ECG findings more commonly found in athletes who
died of a cardiomyopathy (86%) [8].
Variability in disease penetrance is well recognised
with inherited cardiomyopathies, and early pre-
clinical manifestations may only be visible on an
ECG, years before any overt clinical findings.
Abnormal findings may become evident several years
after screening as a result of disease progression [9]. A
longitudinal study of athletes with T-wave inversion
(TWI) showed that 6% of athletes with abnormal
ECGs develop a cardiomyopathy after 12 ± 5 years
[10]. One of the main concerns about ECG screening
in athletes is the number of false-positive tests. Over
the past decade, there have been several evidence-
based refinements in ECG interpretation criteria that
recognise the impact of age, ethnicity and type and
intensity of sporting discipline on the electrical man-
ifestation of the athlete’s heart [1•, 11•, 12]. The most
current international recommendations are associat-
ed with only 3% positive tests in white athletes and
2% in white adolescents, without compromising
specificity [1•, 11•, 13].
On occasion, athletes exhibit profound electrical
repolarisation anomalies, such as TWI that overlaps with
those observed in patients with cardiomyopathy. Simi-
larly, some athletes show a long QT interval or incom-
plete right bundle branch block (RBBB) with J-point
elevation in the absence of symptoms or a relevant
family history of long QT syndrome (LQTS) and
Brugada syndrome respectively. Such athletes are inves-
tigated comprehensively according to established proto-
cols and may train intensively and compete in the ab-
sence of a definitive diagnosis. Given that some of these
athletes could possibly harbour incomplete phenotypic
expression of serious disease, regular monitoring is rec-
ommended and such athletes should be warned about
the symptoms of cardiac disease.
The aim of this review is to highlight the investi-
gation and subsequent surveillance of athletes with
abnormal ECG patterns, focusing on controversial
aspects and gaps in the literature. This review will also
focus on more novel ECG patterns that may simulate
disease.
The athlete’s electrocardiogram
Individuals who engage in at least 4 hours of intensive physical activity
every week undergo structural, functional and electrical adaptations within
the heart that help accommodate the increased demand in cardiac output
[14]. High vagal tone and increased cardiac dimensions are responsible for a
number of physiological ECG changes [1•]. Different demographic factors
influence the degree and type of electrical adaptations, including age, gen-
der, ethnicity and sporting disciplines [15]. Up to 80% of highly trained
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Fig. 1. a Adolescent football player with anterior T-wave inversions and no clinical phenotype. b A basketball player with diffuse ST
depressions identified at screening with no clear phenotype who remains under surveillance. c A young competitive swimmer with
notched T waves and long QT supporting a diagnosis of LQTS. d Professional basketball player with a hypertrophic cardiomyopathy
phenotype. e Recreational athlete complaining of palpitations, found to have right ventricular outflow tract ectopy in the absence
of structural heart disease. f Asymptomatic football player with classical Wolff-Parkinson-White pattern.
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Fig. 1. (Continued)
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athletes will have sinus bradycardia [16]. Over 70% will manifest
repolarisation changes, causing J-point and ST segment elevation [17].
Almost 50% will satisfy ECG voltage criteria for left ventricular hypertrophy
[18] and 12% for right ventricular hypertrophy [19]. Incomplete RBBB is
identified in almost 20% [20], first-degree atrioventricular block (AVB) in
7% [17] and isolated axis deviation in 2% of healthy athletes [17, 19, 21,
22].
A proportion of athletes do however manifest ECG patterns that overlap
with cardiac pathology, including repolarisation and depolarisation abnormal-
ities, ventricular ectopy and high-degree AVB. Given the potential consequences
of failing to identify a serious cardiac condition, several systematic algorithms
are available to investigate such athletes. In the absence of overt disease, annual
surveillance is recommended whilst the athlete is competing. Assessment of
first-degree relatives may provide invaluable clues about possible underlying
pathology.
Dealing with pathological ECG findings in athletes
Different clinical phenotypes will present with a variety of electrical anomalies,
and some electrical patterns are diagnostic (Fig. 1). Evidence regarding disease
progression and arrhythmic risk in most cardiovascular disorders in athletes is
limited. We recommend a holistic approach, focusing on identification of the
clinical phenotype and risk stratification at rest and/or during exercise. In some
cases, detraining may be required to ascertain the significance of profound
repolarisation anomalies such as TWI.
Atrioventricular conduction abnormalities
Among healthy athletes, first-degree and Mobitz type 1 second-degree AVB
reflect high vagal tone at the atrioventricular (AV) node, with or without
intrinsic involvement of the AV node. High-grade AVB, including Mobitz type
2 and complete heart block, are rare and should be considered as a manifesta-
tion of cardiac disease.
Pathological AVB in young athletes may occur secondary to infective myo-
carditis (Lyme’s disease, Chagas disease), immune diseases (cardiac sarcoidosis)
and genetic disorders (PRKAG2 syndrome, myotonic dystrophy, laminin A/C
dilated cardiomyopathy). Relevant serology, genetic and imaging evaluations
should thus be performed, depending on the clinical scenario [1•]. Among
older and middle-aged athletes, cardiac conduction disease is the most likely
aetiology.
Clinical evaluation: Nodal AV block is a manifestation of the athlete’s heart,
typically in the presence of a narrow QRS with an adequate heart rate response
during exercise. Sinus pauses exceeding 3 s were previously considered as a
pathological variant, though this has now been disregarded [23]. AVB at or
below the bundle of His (infra-hissian [nodal] AV block) should always be
considered pathological. A broad QRS, an abnormal axis and an inadequate
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increase in sinus rate response during exercise are useful in confirming conduc-
tion disease. Further evaluation should be carried out to ascertain the aetiology
and risk. Resolution of AVB with appropriate chronotropic response during
exercise implies low risk. Holter monitoring and echocardiography are neces-
sary if response to exercise is unsatisfactory. A case-by-case assessment is rec-
ommended when considering pacemaker implantation, which is dependent on
the site of the AV block, the aetiology and the symptomatic status.
Ventricular depolarisation abnormalities
Ventricular pre-excitation
Ventricular pre-excitation (Wolff-Parkinson-White syndrome (WPW)) oc-
curs when antegrade conduction from the atria to the ventricles takes place
preferentially via a congenital accessary pathway and bypasses the AV node
[13]. WPW is present in 0.1 to 0.3% of athletic and non-athletic individuals
[24]. It may potentially serve as a substrate for SCD in certain
environmental conditions which alter the physiology of the accessory path-
way (electrolytes, temperature, pH). The SCD rate in patients with WPW is
rare at 0.1% per patient year and is up to fourfold higher in symptomatic
individuals [24, 25]. Individuals who engage in intense physical activity are
at a higher risk of developing malignant ventricular arrhythmias, and SCD
[26, 27].
Ventricular pre-excitation may be associated with atrioventricular re-entrant
tachycardia which is usually benign. Aberrant pathways may also serve as
substrates for malignant ventricular arrythmias when co-existing with atrial
fibrillation [28].WPW syndromemay be genetically inherited in 2–4%of cases,
and may also be associated with Ebstein’s anomaly and syndromic hypertro-
phic cardiomyopathy (HCM) due to glycogen storage disorders, most notably
due to mutations in the gamma 2 subunit of adenosine monophosphate-
activated protein kinase (PRKAG2) [29–31].
Clinical evaluation: The evaluation and management options for athletes
with WPW are still debatable. Current consensus recommends starting with
non-invasive risk stratification. An abrupt and complete loss of pre-
excitation during an exercise test suggests a low-risk pathway [32, 33].
Intermittent pre-excitation during sinus rhythm on a resting ECG is also
regarded as a low-risk abnormality [1•, 34]. Excluding structural heart
disease with echocardiography is recommended. An electrophysiological
study (EPS) is preferred if non-invasive testing is inconclusive and is helpful
in determining the shortest pre-excited RR interval (SPERRI) during atrial
fibrillation or rapid atrial pacing. SPERRI measures antegrade conduction
through the accessory pathway. Catheter ablation is recommended in pa-
tients with a SPERRI of ≤ 250 ms (240 bpm), suggesting the accessory
pathway is able to serve as a malignant substrate [32]. The role for EPS as
a first-line diagnostic tool in asymptomatic individuals is debatable. There
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are no randomised studies comparing the event rates in those undergoing
EPS and ablation versus those followed up clinically. EPS may nevertheless
be a first-line option for all competitive athletes who engage in moderate or
high-intensity exercise, irrespective of symptoms or risk, as one cannot
guarantee the same pathway conductance during bouts of high catechol-
amine surges, which are difficult to replicate with non-invasive testing [1•].
Moreover, athletes are at an increased risk of atrial fibrillation, which itself
may pose a risk for SCD if the accessory pathway has the potential for fast
antegrade conduction [27]. The latest ESC guidelines on the management of
supraventricular tachycardia provide a class I recommendation for investi-
gating individuals in high-risk occupations (including athletes) with EPS
and ablating the accessory pathway.
Pathological Q waves
There has been a lack of consensus relating to the definition of a patholog-
ical Q wave. Revised criteria now define a pathological Q wave as a negative
deflection (deep or wide) exceeding ≥ 40 ms or one which has an amplitude
≥ 25% of the following R wave in two contiguous leads (excluding aVR, III
and aVL). A duration of ≥ 30 ms in lead I appeared to offer the greatest
discriminatory value to distinguish athletes from patients with HCM in one
study [35]. Ensuring good lead positioning will help decrease the false-
positive rates as lead misplacement is a common reason for such a pattern
[35].
Pathological Q waves are frequently observed in non-ischaemic cardiomy-
opathy, myocardial infiltration or infarction. They are also present in 1–2% of
apparently healthy athletes where they are localised to the inferior and/or lateral
leads and are more common in male and black athletes [35, 36].
The presence of pathological Q waves warrants further investigation to exclude
cardiomyopathy and myocardial scar. A cardiac magnetic resonance (CMR) imag-
ing scan with stress perfusion imaging will identify structural disease, including
scar, and check for inducible myocardial ischaemia due to coronary artery disease.
QRS fragmentation
Data about QRS fragmentation is not robust. The definition and clinical
relevance of QRS fragmentation were not included in the latest recommen-
dations for ECG interpretation [1•]. Most studies define this phenomenon
as the presence of single or multiple notches in the nadir of the S wave, an
additional R wave (R′) or the presence of 9 1 spiked or slurred R′ in two
contiguous leads. The location or the degree of fragmentation is
however not taken into consideration, which accounts for significant
inter-observer variability [37, 38]. Precise definitions may help in this
regard and enable the differentiation of QRS fragmentation from early
repolarisation which is considered benign in athletes. Early repolarisation
is defined as slurring or notching in the final 50% of the R wave downslope
[39], whereas fragmentation takes place in the S wave, Q wave or first 50%
of the R wave [38].
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Fragmentation has been shown to be associated with myocardial scar
and fibrosis [40]. Its presence in the limb leads has been linked to a higher
risk for SCD in patients with dilated cardiomyopathy, arrhythmogenic
cardiomyopathy, ischaemic cardiomyopathy and Brugada syndrome [41–
43]. The sensitivity of QRS fragmentation in isolation remains to be seen,
and referral for evaluation should be based on the clinical scenario. Our
own experience is to investigate asymptomatic athletes with fragmentation
in the context of a familial cardiomyopathy, Brugada syndrome or sudden
arrhythmic death syndrome.
Low QRS voltage
Low QRS voltage is defined as a QRS amplitude of G 0.5 mV in all frontal leads
and/or G 1.0 mV in all precordial leads. It is present in 1–2% of normal lean
individuals and has been associated with an increased mortality rate in appar-
ently healthy individuals [44]. Our own experience suggests that small QRS
complexes in the limb leads are associated with a scar within the left ventricular
(LV) myocardium in symptomatic athletes, especially when precordial QRS
voltages are normal. In a study of 110 athletes, those with arrhythmias were
statistically more likely to have low QRS voltages if they harboured a scar
compared to those without a scar [45]. Further studies are necessary to evaluate
the significance of low QRS voltages even though they were not considered as a
potential abnormality in the latest recommendations for ECG interpretation
[1•].
Non-specific intraventricular conduction delay
Non-specific intraventricular conduction delay is defined as a QRS duration of
9 110mswithout a specificmorphology. It is commonly reported in the general
population. Such an anomaly is also documented in individuals with cardio-
myopathy and has been linked to a higher risk of cardiovascular death [46, 47].
Its significance in athletes is unclear, but it is thought to occur because of a
combination of high vagal tone and increased myocardial mass [13]. Further
studies are needed to elucidate its clinical significance. At present, further
evaluation is only recommended in asymptomatic athletes if theQRS is severely
prolonged 9 140 ms, regardless of morphology [1•].
Repolarisation abnormalities
T-wave inversion
TWI is often regarded as the electrical hallmark pattern for cardiomyopathies,
with certain patterns and distributions being more suggestive of specific condi-
tions. TWI is also relatively common in athletes [48] and is present in up to 6%
of athletes [18, 20, 49]. Abnormal TWI is defined as an inverted segment of the T
wave in ≥ 2 contiguous leads with a depth of ≥ 1 mm, excluding leads V1, aVR
and III. Despite this definition, groups vary in how they report TWI morphol-
ogy, with some quoting a depth of ≥ 1mm [18, 20, 22, 49], whilst others quote
a depth of ≥ 2 mm [48, 50, 51]. Our own practice is to define TWI as any
negative T-wave deflection because there is no evidence suggesting that a
specific depth is more likely to exclude structural heart disease, nor is there
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any data on the clinical relevance of biphasic, flat or broad-based inverted T
waves.
Anterior T-wave inversions (V1–V4)
Anterior TWI in leads V1–V4 is a relatively common finding in young
asymptomatic individuals aged G 16 years, black athletes and some en-
durance athletes [1•]. In such cases, T waves are often asymmetric or
biphasic and never associated with ST segment depression. TWI in V1–V2 is
regarded as a normal variant in athletes [52]. Among a cohort of 14,646
white athletes and non-athletes, none of those referred for evaluation for
anterior TWI (6.5% of athletes) satisfied criteria for arrhythmogenic car-
diomyopathy (AVC), implying that anterior TWI in isolation is non-specific
for any cardiomyopathy [53].
Influence of age: Anterior TWI is reported in up to 11% of healthy
adolescent athletes [22]. It is regarded as a pre-pubertal variant or
“juvenile” ECG pattern in the absence of symptoms or family history
[18, 22]. The current recommendations use an age of 16 years as the
cutoff for this ECG label [1•], though pubertal development (biological
age) rather than chronological age seems to be independently associ-
ated with the presence of anterior TWI [22, 54]. Right ventricular
dominance and predominant posteriorly directed repolarisation in
young teenagers may explain this phenomenon [55]. The prevalence of
anterior TWI tends to decrease after the age of 16, with only 0.2%
manifesting anterior TWI beyond V2 when aged ≥16 years [18, 22].
Among those with a persistent juvenile ECG pattern at the age of 16,
only 2% persist beyond this age [56].
Influence of sex: Anterior TWI is more common in females (4.3% vs 1.4%)
and extends beyond V2 in 1.2% (versus 0.2% in males) of cases [52].
Shallow TWI morphology in isolation may imply a more benign phe-
notype. The precise significance of this sex difference is uncertain, and it
is possible that chest anatomy in post-pubertal females is conducive to
Anterior TWI [53].
Influence of ethnicity: TWI is more common in black athletes [57]. Anterior
TWI is present in up to 25% of Afro-Caribbean athletes [10, 51, 58]. It is
considered part of the ‘black athlete’s heart’ when preceded by J-point and
concave ST segment elevation [1•, 51].
Influence of sporting discipline: Anterior TWI is reported in up to 14% of
endurance athletes, with electrical remodelling commencing earlier on in
adolescence [59]. Biphasic or bifid TWI extending into lead V3 were re-
ported in 4% of endurance athletes with a structurally normal heart [17].
Right ventricular (RV) remodelling and lateral displacement of the RV may
explain isolated anterior TWI in these athletes [60].
Clinical evaluation: Isolated ATWI in asymptomatic children, black athletes
and endurance athletes should not be over reported [61, 62]. Other ECG
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findings of AVC should be sought such as prolongation of the terminal S-
wave upstroke (≥ 55 ms in V1–V3 in the absence of right bundle branch
block), ventricular ectopy, epsilon waves and low limb lead voltages [61, 63].
CMR imaging is key in the assessment of athletes with abnormal TWI because
echocardiography cannot visualise the right ventricle adequately. CMR can
also help identify LV involvement in such cases [64]. A number of findings
have been shown to be more specific in identifying AVC in athletes [61]. All
three abnormal signal averaged ECG parameters may help identify late QRS
potentials specifically in athletes [61]. Arrhythmia burden and complexity are
important markers of disease. Sustained or on-sustained ventricular tachycar-
dia, multiple couplets and triplets of varying morphology and ≥ 1000 ven-
tricular premature beats are suggestive of AVC [61]. Furthermore, ventricular
tachycardia or increase in VE frequency during stress ECG is another useful
parameter [61]. A low RV fractional area change of ≤ 30% on echocardiogra-
phy or G 45% on CMR, in the presence or absence of regional wall motion
abnormalities or fibrosis on CMR, is useful in diagnosing AVC [61]. All these
investigations may help in the phenotypic characterisation and risk stratifica-
tion of athletes where the clinical suspicion of AVC is high.
Lateral (V5/V6, I, aVL) and inferior (II, III, aVF) T-wave
inversion
Lateral TWI in two or more contiguous leads is uncommon in athletes,
present in 1.5%of athletes. Lateral TWImay occur in isolation or coexist with
inferior TWI [18]. Isolated lateral TWI is present in up to 6% of black athletes
and 1.5% of white athletes [51]. Lateral TWI is associated with a relatively
high yield for cardiomyopathies particularly in white athletes [10, 50]. The
exact significance of isolated inferior TWI is unknown. Our experience sug-
gests that isolated inferior TWI is more common in HCM than in athletes,
which is why current guidelines stipulate comprehensive evaluation [1•].
Clinical evaluation: Lateral TWI is regarded as pathological until proven
otherwise, irrespective of themorphology and depth of the TWI. CMR is key
in establishing a diagnosis, even in the presence of normal echocardiogra-
phy [50]. CMR provides superior spatial resolution to help visualise the LV
apex and myocardial wall thickness and also has the additional benefit of
detecting myocardial fibrosis with gadolinium. Stress ECG and Holter
monitoring will also help by evaluating arrhythmic burden. Comprehen-
sive and serial evaluation is imperative, even in the absence of a clinical
diagnosis, as there is substantial evidence to development of a future
cardiomyopathy in a small proportion of athletes.
ST segment elevation—early repolarisation or Brugada syndrome?
ST segment elevation in the chest leads, often in combination with J-point
elevation, is common in athletes and present in up to 45% of white athletes
and 90% of black athletes [18, 51]. This pattern may overlap with the
Brugada ECG pattern when it occurs in leads V1 and V2. The type 1 Brugada
ECG pattern is diagnostic and is defined as an rSr′ with coved ST elevation
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(STE) ≥ 0.2 mV, broad r′ and inversion of the terminal portion of the T wave
in leads V1–V3.
The type 2 Brugada pattern may, however, be similar to J-point elevation
and elevated ST segments observed in healthy athletes. The r′ with STE may,
however, raise suspicion for the Brugada pattern. Downsloping STE 80 ms
after the ST segment/J point offers a 99% diagnostic accuracy for the
Brugada pattern versus the classic upsloping STE that follows J-point eleva-
tion in athletes [65].
Clinical evaluation: Evaluating STE depends on the specific repolarisation
pattern, presence of TWI, other pathological ECG abnormalities and the clinical
scenario. Isolated J-point elevation in leads V1 and V2 requires no further
evaluation. The type 1 Brugada pattern is however, always regarded as patho-
logical. The latest Shanghai Criteria do not recommend evaluation of the type 2
Brugada pattern in the absence of symptoms and family history [39]. In such
cases, we suggest repeating the ECG with placement of leads V1 and V2 in the
2nd intercostal space. The conversion of the type 2 pattern to the type 1 pattern
with this measure is an indication for confirming the diagnosis with a provo-
cation test with a sodium channel blocking agent [39, 66–68].
Long QT syndrome
LQTS is associated with adrenergicallymediated polymorphic ventricular tachy-
cardia in young individuals. The risk is greatest in individuals with type 1 and 2
LQTS. A consistently prolonged QT interval is one of the hallmarks for LQTS.
Repeating an ECG for borderline cases between 470/480 and 500 ms is advis-
able, whilst prompt referral to a specialist centre is recommended in cases where
QTc is constantly ≥ 500 ms. Athletes should ideally be evaluated more than
48 h after an endurance event because there is an association between endur-
ance exercise and QT prolongation. QT-prolonging medications and electrolyte
abnormalities should be actively sought. The assessment of first-degree relatives
may aid the diagnosis of LQTS. The Schwartz-Moss score is a useful validated
scoring tool which may help evaluate the probability for LQTS, based on ECG
parameters (QTc interval, notched T waves, T-wave alterans, torsades de
pointes, bradycardia), clinical features (syncope) and family history (first-de-
gree relatives suffering from LQTS or history of early SCD). Paradoxical QT
prolongation with increasing heart rate on an exercise test or in the 4th minute
of recovery is suggestive of LQTS [1•]. The unparalleled high yield of genetic
testing in LQTS, reported up to 75%, supports the diagnosis of LQTS and also
offers the possibility of cascade genetic testing in first-degree relatives [69].
One of the challenges in the diagnosis is the accurate assessment of a long
QT interval in athletes. Studies suggest that direct QTmeasurement is inferior to
software-generated values [70], but adhering to the following principles will
help ensure otherwise [71].
1. Use Bazett’s formula (QT corrected for heat rate [QTc] =QT ms/square root
of the previous RR in seconds).
2. The formula can underestimate QTc if the heart rate is G 60 bpm; therefore,
mild exercise is advisable to increase the heart rate. The formulae may also
overestimate QTc at heart rates 9 90 bpm; therefore, a repeat ECG after a
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period of resting is advisable to achieve a lower heart rate.
3. An averageQT interval in the presence of sinus arrhythmia should be obtained.
4. U waves are common in athletes, especially in the anterior chest leads, and
should not be included in the QT assessment. Measuring the QT in leads II
and V5 is advisable as these leads often best delineate the end of the T wave.
5. The ‘teach the tangent method’ is useful in achieving a more accurate QT
assessment. By drawing a tangent to the steepest slope of the last limb of the
T wave in lead II or V5, the intersection with the baseline is regarded as the
end of the T wave.
6. Evaluation of the T-wave morphology (broad, late onset, peaked, notched)
is also important and is invaluable in the diagnosis of congenital LQTS in
athletes with a prolonged QTc [72].
Premature ventricular complexes
Premature ventricular complexes (PVC) are reported in 0.7–2.8% of athletes’
ECGs [73, 74]. Complex arrhythmias are present in 4–10% of athletes with
ectopy [75, 76]. Studies suggest that PVC often disappear during exercise or after
periods of deconditioning [74, 75, 77].
Clinical evaluation: The morphology and complexity of PVCs are two impor-
tant factors that help predict risk. Complex ventricular arrhythmias increase the
risk of structural heart disease up to 15-fold [78]. The origin of the ectopic focus
is also important and is determined by the presence of a RBBB or LBBB
morphology, along with the location of the precordial R-wave transition.
Typically, a PVC with LBBB and inferior axis in V1 suggests a right ventricular
outflow tract origin and is traditionally considered benign [79]. Ectopics with a
broad RBBB morphology originate from the LV and are more likely to be
associated with structural abnormalities [78, 80], highlighting the need for a
comprehensive structural assessment in these athletes. It is, however, important
to emphasise that not all cases may concur with these general observations;
hence, every case should be managed separately. PVCs with a RBBB morphol-
ogy may also represent a fascicular focus which is classically considered to be
benign, rather than implying LV pathology. Conversely, PVCs with a LBBB
morphology and inferior axis may be amanifestation of AVC, though a number
of factors in QRS morphology may help discern the latter from benign right
ventricular outflow tract ectopy [80]. A QRS duration of more than 160 ms,
initial QRS slurring, QS pattern in lead V1 and a QRS axis greater than 90° have
been shown to be more common in patients with AVC compared to patients
with idiopathic right ventricular outflow tract ectopy [80]. Ultimately, EPS may
be necessary to map ectopic foci and risk stratify the clinical phenotype, partic-
ularly in cases were ablation may be a therapeutic option.
Athletes with frequent PVCs should undergo comprehensive investigation
to exclude structural heart disease, exercise stress testing and prolonged ECG
monitoring [81]. Exercise-induced ventricular arrhythmias are regarded as ob-
jective markers for adverse cardiac events [82]. The likelihood of structural heart
disease is higher in exercise-induced arrhythmias [79], which is why stress
testing is an integral part of the evaluation for all those who engage in intense
physical activity.
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A PVC burden of ≥ 2000/24 h has been shown to increase the likelihood of
structural heart disease [74], with a higher yield of up to 70% when co-existing
with repolarisation abnormalities [83]. A burden exceeding 15% has generally
been reported to confer a higher risk for LV dysfunction [76, 78], which is why
comprehensive evaluation of ectopic burden with Holter monitoring and ex-
cluding structural heart disease with echocardiography is important, using CMR
when clinically relevant.
Conclusion
Significant advances have beenmade in improving the sensitivity and specificity
of current ECG criteria in athletes [1•]. Subjects with pathological ECG variants
may, however, not satisfy current clinical criteria for a suspected phenotype,
whilst the relevance of certain patterns are still under investigation. Variable
penetrance of some of the disorders in question may, however, complicate
matters, which is why current recommendations suggest serial surveillance in
athletes with pathological ECG findings [9]. New imaging techniques in com-
bination with more contemporary tools such as genetic testing can contribute
towards establishing a clinical diagnosis, predicting prognosis, guiding therapy
and offering the opportunity for cascade family screening [84]. Genetic evalu-
ation for instance may one day better define a clinical phenotype.
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